title: Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Brian L
authors.initials: BL
authors.lastname: Burnette
authors.forename: Mark A
authors.initials: MA
authors.lastname: Jentoft
authors.forename: Luis F
authors.initials: LF
authors.lastname: Porrata
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Boyce
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Witzig
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D001921:Brain / Q000473:pathology*; D002330:Carmustine / Q000008:administration & dosage; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D002585:Cesarean Section; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008558:Melphalan / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D011034:Podophyllotoxin / Q000008:administration & dosage; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy*; D011256:Pregnancy Outcome; D000069283:Rituximab; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab; D003907:Dexamethasone; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine; D008727:Methotrexate